Nanopharmaceutics, Inc.

Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company focused on developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company specializes in nanoparticle and fine-particle formulations to improve the delivery of hard-to-administer BCS category II and IV drugs, with a key emphasis on enhancing drug absorption and stability. Founded in 2018, Nanopharmaceutics operates within the Biotechnology and Pharmaceutical industries. Although specific headquarters and recent investment details are not available, the company's mission to advance specialized pharmaceutical products holds promise for potential investors and partners. Nanopharmaceutics' dedication to addressing critical medical needs in cancer, CNS disorders, and infectious diseases positions it as an intriguing prospect within the pharmaceutical startup landscape.